23 January 2005

EPO limits cancer gene patent

Political and scientific groups last week succeeded in reducing the scope of a human gene patent used to facilitate the diagnosis of breast and ovarian cancer in women

Political and scientific groups last week succeeded in reducing the scope of a human gene patent used to facilitate the diagnosis of breast and ovarian cancer in women.

Following a two-day hearing, the European Patent Office (EPO) on January 21 ruled in favour of reducing the scope of a European patent to the human BRCA1 gene from around 30 to just three claims.

The rest of this article is available to subscribers to Managing IP only.

Managing IP subscribers also have access to Managing Patents, Trade marks and Copyright until 30th October 2010.
Managing IP trialists have access to Managing Patents, Trade marks and Copyright for 48-hours.

Subscribe today for full access to this article. Alternatively, take a 48-hour free trial giving you access to the current content.

If you are already a subscriber please log in (see top right column) to access the rest of this article.

Managing Intellectual Property

Navigation Menu

Managing IP Home Page

Managing IP Products

Browse Magazine

IP Resources

EPO limits cancer gene patent

The rest of this article is available to subscribers to Managing IP only.

Events